HCPCS Level II code J9029 describes an intravesical instillation of nadofaragene firadenovec-vncg administered per therapeutic dose, a localized gene therapy delivery into the bladder; service type: intravesical therapeutic instillation; typical site of service: outpatient clinic or hospital outpatient department where bladder-directed procedures are performed.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Antibody-Drug Conjugates, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only).